Back to results
US 10,519,247 B2Granted
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
AssigneeBoard of Regents, The University of Texas System
InventorsE. Sally Ward, Raimund Ober, Jeffrey Kang, Jayakumar Poovassery
Life of this patent
Estimating the term…
Abstract
The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.
Claims12
A bispecific antibody comprising:
- an anti-HER2 antibody comprising two heavy chains and two light chains and an anti-HER3 single chain antibody variable fragment (Fv) comprising a heavy chain variable domain and a light chain variable domain, wherein said Fv is linked to each of the two CH3 domains of the anti-HER2 antibody, wherein the light chain variable domain of the anti-HER3 single chain Fv comprises amino acid residues 607-717 of SEQ ID NO:
- 1 and the heavy chain variable domain of the anti-HER3 single chain Fv comprises amino acid residues 473-591 of SEQ ID NO:
- 1, wherein the light chain variable domain of the anti-HER2 antibody comprises amino acid residues 20-127 of SEQ ID NO:
- 2 and the heavy chain variable domain of the anti-HER2 antibody comprises amino acid residues 20-139 of SEQ ID NO:
- 1, and wherein the bispecific antibody facilitates formation of HER2-HER3 heterodimers and inhibits the growth or proliferation of a cancer cell when administered or applied at a therapeutically effective amount and in combination with a tyrosine kinase inhibitor.
2 more elements
Dependencies are inferred from the claim text.